Company Overview and News

219
AXON / Axovant Sciences Ltd. 424B5 (Prospectus)

23h sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
AXON

224
AXON / Axovant Sciences Ltd. 8-K (Current Report)

23h sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
AXON

212
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug

2018-06-19 zacks
Shares of Solid Biosciences Inc. (SLDB - Free Report) surged 10.9% after the company announced that the FDA has lifted the clinical hold on its phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001.
NEE.PRI NEE.PRJ SLDB NEE.PRC OXB NEE.PRQ NEE.PRR OXBDF NEE AXON

214
Axovant's Parkinson's Gene Therapy Is Extremely Risky

2018-06-19 seekingalpha
Axovant purchased an experimental Parkinson's gene therapy and is expected to start a clinical trial later this year.
ARNA OXB OXBDF AXON

211
Axovant to Present at First Annual Roivant Pipeline Day

2018-06-18 globenewswire
BASEL, Switzerland, June 18, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET.
AXON

221
AXON / Axovant Sciences Ltd. DEF 14C

2018-06-18 sec.gov
QuickLinks -- Click here to rapidly navigate through this document
AXON

257
Cramer's lightning round: I missed Tandem Diabetes' stock's 700% run

2018-06-15 cnbc
Tandem Diabetes Care: "This is one of the hottest stocks I've ever seen. It's up, like, 700 percent. I feel like I've missed it. I am not the call. I've got to be careful to recommend a stock after this kind of run, so I'm going to pass."
HD GLOP.PRA GLOP.PRB GLOP TNDM MO AXON

217
Gene Therapy Prospects Make Axovant Sciences A Compelling Buy For 2018

2018-06-15 seekingalpha
Axovant Sciences' (AXON) licensing deal with Oxford BioMedica (OTCPK:OXBDF) is nothing short of a masterstroke. This deal has opened up the gene therapy segment for Axovant Sciences and has positioned the company to make a solid entry in the neurodegenerative disease segment. This transformation from being a small molecule player to a very potent lentiviral vector gene therapy company initially targeting Parkinson's disease or PD has been well received by the investor community.
OXB NVS OXBDF SNY AXON

451
Avoiding The 'Black Hole' Of Disease Development

2018-06-15 seekingalpha
Both large and small concerns continue to see nothing but failure in the Alzheimer's space despite spending billions on development efforts.
MDGL GILD AZN GLMD ICPT LLY VKTX VTVT VKTXW AZN JNJ MRK CNAT ABBV ABBV AXON

370
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

2018-06-13 zacks
The biotech sector was in focus last week with regular pipeline updates and collaboration/licensing deals. While biotech bigwig Amgen’s (AMGN - Free Report) drugs won both FDA and EC approvals, Axovant (AXON - Free Report) soared on a licensing deal Oxford BioMedica. Meanwhile, Regeneron (REGN - Free Report) collaborated with Zoetis to discover new veterinary treatments.
AMGN ALXN BIIB OXB OXBDF AXON

216
Axovant Sciences: Expect A Crash After An Overhyped Deal With Oxford BioMedica

2018-06-12 seekingalpha
Axovant Sciences skyrocketed after a licensing agreement with Oxford BioMedica and investment by Roivant, resulting in a $373 million increase to its valuation.
IMDZ OXB LNSTY OXBDF AXON

290
Top Ranked Momentum Stocks to Buy for June 12th

2018-06-12 zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 12th:
APC ATHX TRI AEUA AXON

AXON : Axovant Sciences Stock Analysis and Research Report

2017-11-09 - Asif

Axovant Sciences is a clinical-stage biopharmaceutical company dedicated to advancing treatments for patients with life-altering neurologic conditions. To date, its primary focus has been on developing intepirdine, an orally administered antagonist of the 5-HT 6 receptor, for the treatment of Alzheimer's disease and dementia with Lewy bodies, or DLB, and its second product candidate, nelotanserin, a potent and highly selective inverse agonist of the 5-HT 2A receptor, for the treatment of visual hallucinations in patients with Lewy body dementia, or LBD, movement disorder symptoms in patients with DLB and REM behavior disorder, or RBD, in patients with LBD. In September 2017, the company announced that the Phase 3 MINDSET clinical trial of 35 mg intepirdine in patients with mild-to-moderate Alzheimer's disease who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. Axovant Sciences is continuing to advance the products in its pipeline, focusing on...

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to AXON / Axovant Sciences Ltd. on message board site Silicon Investor.

Axonyx Inc (AXYX) Axion Spatial Imaging Ltd. (AXON)
Axonyx Inc. (NasdaqSC:AXYX) Saxon Petroleum (SXN-TSE)
CUSIP: G0750W104